There is only a pending partnership with the bankruptcy court. NASH is over for CYDY. The RCT trial failed as the company said. The 350mg group now seems like noise and BP is not interested in that. Leronlimab now seems destined to be a lab drug for universities to play around with now and then - but that it about it.
News 
Market Data 
Discover 
